The Brazilian Journal of Infectious Diseases The Brazilian Journal of Infectious Diseases
Braz J Infect Dis 2017;21:133-9 - Vol. 21 Num.2 DOI: 10.1016/j.bjid.2016.11.008
Original article
Factors associated with pain in individuals infected by human T-cell lymphotropic virus type 1 (HTLV-1)
Dislene N. dos Santosa,b,c, Kionna O.B. Santosb, Alaí B. Paixãob, Rosana Cristina P. de Andradec, Davi T. Costac,d, Daniel L. S-Martinb,e, Katia N. Sáb,f, Abrahão F. Baptistaa,b,f,,
a Universidade Federal da Bahia, Programa de Pós-graduação em Medicina e Saúde, Salvador, BA, Brazil
b Universidade Federal da Bahia, Laboratório de Eletroestimulação Funcional, Salvador, BA, Brazil
c Universidade Federal da Bahia, Hospital Professor Edgard Santos, Serviço de Imunologia, Salvador, BA, Brazil
d Universidade Estadual do Sudoeste da Bahia, Vitoria da Conquista, BA, Brazil
e Universidade Federal da Bahia, Faculdade de Medicina da Bahia, Salvador, BA, Brazil
f Escola Bahiana de Medicina e Saúde Pública, Pós graduação e pesquisa, Salvador, BA, Brazil
Received 05 May 2016, Accepted 22 November 2016
Abstract
Introduction

Despite the high prevalence of chronic pain in individuals infected with HTLV-1, predictive and protective factors for its development are still unclear.

Objective

To identify factors associated with chronic pain in individuals with HTLV-1.

Methods

This cross-sectional study was conducted in a reference center for treatment of patients infected with HTLV-1 in Salvador, Bahia, Brazil. The study included individuals infected with HTLV-1, over 18 years, and excluded those with difficulty to respond the pain protocol. Data on sociodemographic, health behavior, and clinical characteristics were collected in a standardized way. The prevalence ratio (PR) of pain is described, as well as the factors independently associated with the presence of pain, which were assessed by multiple logistic regression.

Results

A total of 142 individuals were included in the study, mostly female (62.7%), aged 20–64 years (73.2%), married (61.3%), with less than eight years of education (54.2%), and with a steady income (79.6%). Multivariate analysis showed that being symptomatic for HTLV-1 – sensory manifestations, erectile dysfunction, overactive bladder, and/or HAM/TSP (PR=1.21, 95% CI: 1.05 to 1.38), self-medication (PR=1.29, 95% CI: 1.08–1.53), physiotherapy (PR=1.15, 95% CI: 1.02–1.28), and depression (PR=1.14, 95% CI: 1.01–1.29) were associated with an increased likelihood of presenting pain. On the other hand, physical activity (PR=0.79, 95% CI: 0.67–0.93) and religious practice (PR=0.83, 95% CI: 0.72–0.95) were associated with a decreased likelihood of having pain.

Conclusion

The use of self-medication, physiotherapy and the presence of depression are independently associated with neurological symptoms in HTLV-1 infected patients. Religious practice and physical activity are both protective for the development of pain.

Keywords
Human T-cell lymphotropic virus type I (HTLV-1), Tropical spastic paraparesis, Retroviridae infections, Chronic pain
Introduction

Human T-cell lymphotropic virus type 1 (HTLV-1) is a retrovirus that infects millions of people throughout the world.1,2 This virus is endemic in the Caribbean, West and Central Africa, South America, and Japan.3 In Brazil, the national prevalence is unknown, but there are differences among geographical regions.4,5 Salvador, the major city in the Northeastern of Brazil, has around 1.76% of its population infected with the virus and is considered to have the second highest number of cases in the country.5,6

Clinical and neurological manifestations of the disease caused by HTLV-1 are multiple. The HTLV-1 associated myelopathy/tropical spastic paraparesis (HAM/TSP) and Adult T-cell leukemia/lymphoma (ATL) are the worst clinical manifestations of this disease, affecting around 5.0% of infected patients.3,7 Uveitis,8 poliomyositis, arthropathy,9,10 sicca syndrome, urologic disturbances,10,11 and peripheral neuropathy12,13 are also described. However, the majority of infected people remains asymptomatic and do not present any clinical manifestations.

Painful complaints are present in 84.3% of subjects with HTLV-1 regardless of neurological signs and symptoms,14 underscoring the need for preventive actions for pain management in these patients. Pain is correlated to worsening of the infection and is probably associated with increased expression of pro-inflammatory cytokines.15,16 When myelopathy is present, the pain tends to be chronic,17 reducing functional capacity,18,19 and increasing the likelihood of psychological symptoms.20 It is also associated with a negative impact on quality of life and individual autonomy.19,21

Few studies to date have investigated pain symptoms in infected individuals without myelopathy. Therefore, it is important to determine whether pain could be considered a characteristic of HTLV-1 infection.22 A better understanding of the pain phenomena in patients without myelopathy could inform health policies aiming to prevent the negative impact of pain in patients with HTLV-1. Thus, this study aimed to identify factors associated to nociceptive and neuropathic chronic pain in patients with symptomatic and asymptomatic HTLV-1.

Material and methods

This cross sectional study was conducted at a reference center for the treatment of patients infected with HTLV-1, the Magalhães Neto Ambulatory care unit at the Hospital Professor Edgard Santos in Salvador-BA, Northeast of Brazil. HTLV-1 seropositive patients are commonly referred from blood banks, clinics and hospitals in the region to this center.

Sample selection consisted of inviting daily the first three individuals scheduled for the neurologist appointment, which categorized the patients according to the criteria described bellow. Data collection occurred between July 2012 and January 2014.

Individuals diagnosed with HTLV-1 by antibodies detection using ELISA method (Cambridge Biotech, Worcester, MA) and confirmed by the Western blot test (HTLV Blot 2.4, Genelabs, Science Park Drive, Singapore) were included in the study. Individuals over 18 years old, with or without pain, were assessed by a neurologist using the neurological scales Extended Disability Status Scale (EDSS) and Osame Motor Dysfunction Scale (OMDS).23,24 Patients were stratified according to criteria established by Castro Costa (2006)22 as “asymptomatic” (EDSS=0/Osame=0); “possible or probable HAM/TSP” (EDSS<2/Osame=0); and “defined HAM/TSP” (EDSS2/Osame>1). Individuals with difficulties to answer the pain evaluation protocol were excluded. The number of participants was defined by a sample size calculation powered to detect a difference in pain prevalence of 80% between subjects with and without myelopathy, with a confidence interval of 95%.14

Sociodemographic and clinical data were collected through a standardized form administered by a single trained examiner. Chronic pain was defined as continuous or recurrent pain for six months or more.25 The Hospital Anxiety and Depression Scale (HADS) was used to search for symptoms suggestive of anxiety and depression.26 Pain location, intensity, and type (nociceptive or neuropathic) were also registered, but are not presented here, as their discussion is out of the scope of this study.

Variables of interest

The dependent variable was chronic pain (dichotomous 0/1), while the independent variables included sociodemographic, clinical, and behavior characteristics, as well as comorbidities (rheumatologic disease, hypertension, diabetes, sickle cell anemia, systemic lupus erythematosus, myasthenia gravis, polymyositis, osteoporosis, osteopenia, osteoarthritis, esophageal reflux, gastric ulcer, umbilical hernia, disc herniation, hemorrhoids, psoriasis, heart disease, and occupational diseases). Use of medications for pain was self-reported (taking medicines without prescription or reusing previous prescription) and also verified at the patient's medical chart (list of medications prescribed by a physician). Patients were classified regarding the neurological manifestations related to HTLV-1 in symptomatic (sensory manifestations, erectile dysfunction, overactive bladder, and/or HAM/TSP) and asymptomatic patients.

Data analysis was done in three steps. In the first descriptive step, it was calculated the absolute and relative frequencies, central tendency and dispersion measures of the variables of interest. In the second step it was performed univariate analysis using the prevalence ratio as a measure of association and the respective 95% confidence intervals (95% CI), considering p<0.05 as a parameter for statistical significance. To assess the simultaneous effect of variables, it was conducted a multiple logistic regression analysis of exploratory nature (MLRA), seeking to assess the independent association of the dependent variable with the covariates under study.

The backward MLRA was conducted according to the procedures recommended by Hosmer and Lemeshow, with the pre-selection of variables for inclusion in the analysis made by the likelihood ratio test, adopting a p-value ≤0.25. A p-value <0.05 was adopted to obtain the final model. In order to adjust the association measure, it was used the robust method of Poisson for prevalence ratio (PR) estimates, to correct the overestimation of OR and appropriate confidence intervals.27

The Ethics Committee from Hospital Universitário Professor Edgard Santos, Federal University of Bahia/UFBA (Protocol 21/2011), approved this study. All participants signed an Informed Consent Form.

Results

Of the 160 individuals with HTLV-1 screened for this study, 18 (11.25%) were excluded because they reported presence of pain for less than six months, did not fill all the evaluation protocol, or refused to participate. Of the remaining 142 participants, the majority was female (62.7%), aged 20–64 years (73.2%), and lived with a partner (61.3%). Regarding education and earnings, 54.2% of subjects had less than eight years of education and 79.6% had steady salary, 9.2% reported use of tobacco, 43.3% had regular alcohol consumption, 41.5% performed physical exercise for three or more days a week, and 59.2% admitted some religious practice (Table 1).

Table 1.

Demographic and health behavior characteristics of individuals with HTLV-1.

Variable (N=142)  Frequency
  n  (%) 
Sex     
Female  89  62.7 
Male  53  37.3 
Age     
≥65  38  26.8 
< 65  104  73.2 
Marital status     
Without a partner  55  38.7 
With a partner  87  61.3 
Education     
≤8 years of schooling  77  54.2 
>8 years of schooling  65  45.8 
Steady income     
No  29  20.4 
Yes  113  79.6 
Smoking     
Yes  13  09.2 
No  129  90.8 
Alcoholisma     
Yes  61  43.3 
No  80  56.7 
Physical exercise     
Yes  59  41.5 
No  83  58.5 
Religious practicea     
Yes  84  60.0 
No  56  40.0 

HTLV-1, Human T-cell lymphotropic virus type 1.

a

Missing data.

The overall prevalence of chronic pain was 81.7%. Regarding the clinical characteristics and lifestyle behaviors among participants, 54.2% were defined as asymptomatic HTLV-1 and 52.8% had at least one comorbidity. The majority had no anxiety or depression (75.4%) and had self-medication habit (61.5%) (Table 2). The comorbidities potentially related to pain (listed in methods section) were present in 51.7%. Symptomatic EDSS<2/Osame=0 was observed in 28.4%, EDSS2/Osame>1 in 23.3%, and asymptomatic EDSS=0/Osame=0 in 48.3%. Of the patients who complained from pain, only 26.7% reported physiotherapy.

Table 2.

Clinical and lifestyle characteristics of patients with HTLV-1.

Variable (N=142)  Frequency
  n 
Neurological symptoms of HTLV 1     
Symptomatic with/without pain  56/09  40.6/07.7 
Asymptomatic with/without pain  60/17  37.1/14.6 
Comorbidity     
Yes  75  52.8 
No  67  47.2 
Psychoaffective symptoms     
Anxiety     
Yes  49  34.5 
No  93  65.5 
Depression     
Yes  45  31.7 
No  97  68.3 
Anxiety and depression     
Yes  35  24.6 
No  107  75.4 
Pain treatment     
Physiotherapy     
Yes  33  23.2 
No  109  76.8 
Medication with pain action     
Yes  49  33.1 
No  95  66.9 
Self-medication habit     
No  55  38.7 
Yes  87  61.3 

HTLV-1: Human T-cell lymphotropic virus type 1.

Pain was more prevalent among women (85.4%) than men (75.5%), although the difference was not statistically significant (p=0.10). Subjects symptomatic for HTLV-1 (PR=1.26, 95% CI: 1.08–1.48), with less than eight years of education (PR=1.22, 95% CI: 1.03–1.45) and doing physiotherapy for treating pain (PR=1.20, 95% CI: 1.05–1.37) were more likely to present chronic pain (Tables 3 and 4). Chronic pain was also associated with lifestyle and clinical characteristics (Table 4). Patients that reported practice of weekly physical activity (PR=0.74, 95% CI: 0.61–0.89) were less likely to present chronic pain. Conversely, those who self-medicated (PR=1.29, 95% CI: 1.07–1.57), had symptoms of anxiety (PR=1.24, 95% CI 0.08–1.43), and depression (PR=1.27, 95% CI: 1.11–1.44) were more likely to present chronic pain.

Table 3.

Prevalence of chronic pain according to socio-demographic variables of individuals with HTLV-1.

Variable (N=116)  n  PR  95% CI  p 
Sex           
Female  76  85.4  1.13  0.94–1.34  0.10 
Male  40  75.5  1.00  –   
Age           
≥65 years  31  81.6  1.00  0.83–1.19  0.90 
<65 years  85  81.7  1.00  –   
Marital status           
Without a partner  47  79.3  1.07  0.92–1.25  0.30 
With a partner  69  85.5  1.00     
Education           
≤8 study years  69  89.6  1.22  1.03–1.45  0.01a 
>8 study years  47  72.3  1.00  –   
Steady income           
No  92  81.4  1.01  0.84–1.22  0.80 
Yes  24  82.8  1.00  –   

PR, Poisson for prevalence ratio; IC, confidence intervals.

HTLV-1, Human T-cell lymphotropic virus type 1.

a

p<0.05.

Table 4.

Prevalence of chronic pain according to lifestyle and clinical conditions of patients with HTLV-1.

Variable  n  PR  95% CI  p-Value 
Lifestyle           
Alcoholism           
Yes  49  80.3  0.95  0.81–1.12  0.599 
No  67  83.8  –  –   
Smoking           
Yes  10  76.9  0.92  0.68–1.26  0.597 
No  106  82.8  –  –   
Physical exercise (≥3 days)           
Yes  40  67.8  0.74  0.61–0.89  <0.001a 
No  76  91.6  –  –   
Religious practice           
Yes  65  77.4  0.86  0.74–1.00  0.072 
No  50  89.3  –  –   
Self-medication habit           
Yes  78  89.7  1.29  1.07–1.57  0.002a 
No  38  69.1  –  –   
Clinical features           
Neurological symptoms in HTLV-1           
Symptomatic  60  92.3  1.26  1.08–1.48  0.002a 
Asymptomatic  56  72.7  –  –   
Comorbidity           
Yes  60  80.0  0.95  0.81–1.11  0.583 
No  56  83.6  –  –   
Pain treatment           
Physiotherapy           
Yes  31  93.9  1.20  1.05–1.37  0.038a 
No  85  78.0  –  –   
Psychoaffective symptoms           
Anxiety           
Yes  46  93.9  1.24  1.08–1.43  0.006a 
No  70  75.3  –  –   
Depression           
Yes  43  95.6  1.27  1.11–1.44  0.003a 
No  73  75.3  –  –   

PR, Poisson for prevalence ratio; IC, confidence intervals.

HTLV-1, Human T-cell lymphotropic virus type 1.

a

p<0.05.

In the MLRA analysis, the presence of neurological symptoms associated with HTLV-1 (being symptomatic), depression, self-medication, and physiotherapy remained independently associated with increased likelihood of presenting chronic pain. Individuals classified as symptomatic were 1.21 times more likely to present painful symptoms than asymptomatic HTLV-1 patients (95% CI: 1.05–1.38). Those who self-medicated were 1.29 times more likely to report chronic pain than those who did not have this habit (95% CI: 1.08–1.53). Physical activity (95% CI: 0.67–0.93) and religious practice (95% CI: 0.72–0.95) were factors associated with a decrease likelihood of chronic pain. The physical activity reduced the likelihood of chronic pain by 21%, while report of a religious practice reduced it by 17% (Table 5).

Table 5.

Prevalence ratios (PR) adjusted with their respective confidence intervals (CI) of 95% among the factors associated with chronic pain.

Variables  PR  CI (95%) 
Neurological symptoms in HTLV-1     
Symptomatic  1.21  1.05–1.38 
Asymptomatic  1.00  – 
Depression     
Yes  1.14  1.01–1.29 
No  1.00  – 
Self-medication     
Yes  1.29  1.08–1.53 
No  1.00  – 
Physiotherapy     
Yes  1.15  1.02–1.28 
No  1.00  – 
Physical exercise     
Yes  0.79  0.67–0.93 
No  1.00  – 
Religious practice     
Yes  0.83  0.72–0.95 
No  1.00  – 

HTLV-1, Human T-cell lymphotropic virus type 1.

Discussion

This study aimed to investigate factors associated with chronic pain in patients with HTLV-1, identifying their strength of association. The magnitude of these associations was not reported in previous studies, especially in patients with HAM/TSP.14,21,28

Individuals with neurological symptoms associated with the virus (symptomatic individuals) were more likely to report pain. This group usually has a higher pro-viral load and increased cytokines expression that indicates an inflammatory process.29,30 The inflammation mainly affects the thoracic spinal cord segment31 and leads to weakness in the lower limbs (paraparesis) accompanied by hyperreflexia and Babinski signal.7,10,12 The worsening of neurological symptoms cause muscle impairment, postural and joint instability18,21,32 that are potential sources of pain and also lead to adjacent tissue injury, such as joint capsules and ligaments, muscles and peripheral nerves. The involvement of the posterior column of the spinal cord33 interferes with proprioception and vibratory sensation in the lower limbs,7,34 which also contributes to this injury cycle.

Depression increased the likelihood of chronic pain in patients with HTLV-1 in this study. The overall prevalence of depressive symptoms were 31.7%, and were found to be independently associated with chronic pain. A previous study reported a frequency of moderate to severe depression in 59% HAM/TSP and in 22% asymptomatic patients.20 Psycho-affective problems are often associated with other diseases. Moreover, in most cases, it leads to worsening of the evolution of both the psychiatric disorder and the disease itself, with higher morbidity and mortality. This symptom is often underdiagnosed and has irregular therapeutic assistance, notably the lack of differential diagnosis for chronically ill patients.35

The relationship between self-medication and chronic pain points to a typical behavior of subjects affected by prolonged exposure to pain. The practice is common among individuals with chronic diseases, elderly and female,36,37 common characteristics in the population with HTLV-1. Symptoms suggestive of infection such as weakness, tiredness, and pain in lower limbs12 may be concealed by self-medication, delaying diagnosis of the disease and consultation with a specialist. Among the medications with indiscriminate use, the most frequent was anti-inflammatory drugs, which can irritate the gastric mucosa and lead to renal injury,38,39 conditions that should be better monitored in individuals infected by the virus.

In this study, individuals who were more likely to have pain were in physiotherapy, which has as one of its main objectives the inhibitory modulation of pain by reducing peripheral and central stimuli that sensitize the nervous system.40 As cross-sectional studies do not establish causal relationship, it is difficult to establish whether this association is due to the demand for treatment of pain or physiotherapy itself causes more pain in patients. The few clinical trials that tested the efficacy of physiotherapy in patients with HTLV-1 showed that therapeutic exercise can be useful in reducing pain intensity, and improving quality of life.41,42 For this reason, our hypothesis is that the strength of association found in this study is related to worse pain conditions. The professionals assisting patients with pain usually try to control it with medication and rest, postponing indication of physiotherapy for later, limiting the resources available for the treatment of painful symptoms. Multidisciplinary centers of assistance for individuals infected with HTLV-1 should refer patients to physiotherapy early on, even before the complaint of pain.

The positive impact on pain of regular physical activity in patients with HTLV-1 reinforces the idea that regular exercise has numerous benefits for people with chronic pain,43 although its analgesic effectiveness is questioned.43,44 Exercising has regulatory action in the endogenous mechanisms of pain control and may be useful in reducing anxiety, depression, and mental disabilities. It also improves self-esteem, social participation, intellectual and physical productivity.43 It is likely that regular exercise is one of the best ways to control pain in this condition. Cohort studies comparing the evolution of painful symptoms in HTLV-1 infected active individuals with those who are inactive can help testing this hypothesis.

In this study, admitting to have faith was associated with a lower likelihood of chronic pain complaints. This finding indicates the important role of belief and attitude among chronically ill patients. A positive impact of religiosity in the relearning process to deal with a new uncomfortable condition of life has been reported.45 The creed has a positive influence on health, particularly for mental health through changes in lifestyle and social support.46 Religious practices is positively associated with psychological well-being and life satisfaction indicators.45 Individuals with high levels of stress or in fragile situations such as elderly, people with physical disabilities and severe clinical disease are the most benefited with religiosity.46 Studies in chronic patients about spirituality and faith show the relevance of this issue in the doctor–patient relationship and in changing the look on life and fighting the disease.45,46

The major limitation of this study is the lack of comparison between HTLV-1 participants with an uninfected control group. Longitudinal studies are recommended to establish causal relationship with greater accuracy, in contrast to cross-sectional studies. The findings presented here add to the understanding of chronic pain in patients with HTLV-1 by describing the strength of the association between pain symptoms and clinical/demographical factors, which may help in future researches and in clinical decisions.

Conflicts of interest

The authors declare no conflicts of interest.

Acknowledgments

We wish to acknowledge Dr Edgar de Carvalho, Coordinator of the Multidisciplinary HTLV Ambulatory of Professor Edgard Santos Hospital for allowing this work to be held at this facility. This study was funded by National Council for Scientific and Technologic Development (CNPq), and the Coordination of Improvement of Higher Level Personnel (CAPES). We also acknowledge Fernanda Costa Queirós, Janine Ribeiro Camatti and Iasmyn Adélia Victor Fernandes de Oliveira for their valuable contribution in assessing the participants and for the critical review of the manuscript.

References
1
A. Gessain,O. Cassar
Epidemiological aspects and world distribution of HTLV-1 infection
Front Microbiol, 3 (2012), pp. 1-23 http://dx.doi.org/10.3389/fmicb.2012.00001
2
C. Hlela,S. Shepperd,N.P. Khumalo,G.P. Taylor
The prevalence of human T-cell lymphotropic virus type 1 in the general population is unknown
AIDS Rev, 11 (2009), pp. 205-214
3
H. Vrielink
HTLV-I/II prevalence in different geographic locations
Transfus Med Rev, 18 (2004), pp. 46-57
4
A.B.F. Carneiro-Proietti,J.G.R. Ribas,B.C. Catalan-Soares
Infecção e doença pelos vírus linfotrópicos humanos de células T (HTLV-I/II) no Brasil
Rev Soc Bras Med Trop, 35 (2002), pp. 499-508
5
B. Catalan-Soares,AB de F. Carneiro-Proietti,F.A. Proietti
Heterogeneous geographic distribution of human T-cell lymphotropic viruses I and II (HTLV-I/II): serological screening prevalence rates in blood donors from large urban areas in Brazil
Cad Saude Publ, 21 (2005), pp. 926-931
6
I. Dourado,L.C.J. Alcantara,M.L. Barreto,M. Teixeira,G. da,B. Galvão-Castro
HTLV-I in the general population of Salvador, Brazil: a city with african ethnic and sociodemographic characteristics
J Acquir Immune Defic Syndr, 34 (2003), pp. 527-531
7
A.Q.C. Araujo,M.T.T. Silva
The HTLV-1 neurological complex
Lancet Neurol, 5 (2006), pp. 1068-1076 http://dx.doi.org/10.1016/S1474-4422(06)70628-7
8
K. Kamoi,M. Mochizuki
HTLV-1 uveitis
Front Microbiol, 3 (2012), pp. 1-4 http://dx.doi.org/10.3389/fmicb.2012.00001
9
M.M.N. de Carvalho,A.E. Novaes,E.M. De Carvalho,M.I. Araújo
Doenças reumáticas auto-imunes em indivíduos infectados pelo HTLV-1
Rev Bras Reumatol, 46 (2006), pp. 334-339
10
S.K.W. Poetker,A.F. Porto,S.P. Giozza
Clinical manifestations in individuals with recent diagnosis of HTLV type I infection
J Clin Virol, 51 (2011), pp. 54-58 http://dx.doi.org/10.1016/j.jcv.2011.02.004
11
M.F. Caskey,D.J. Morgan,A.F. Porto
Clinical manifestations associated with HTLV type I infection: a cross-sectional study
AIDS Res Hum Retroviruses, 23 (2007), pp. 365-371 http://dx.doi.org/10.1089/aid.2006.0140
12
D. Tanajura,M. Glesby,E. Carvalho
Sensory symptoms and immune response in individuals infected with HTLV-1
Clin Exp Med Sci, 1 (2013), pp. 1-14
13
M. Saeidi,P. Sasannejad,M. Foroughipour,S. Shahami,A. Shoeibi
Prevalence of peripheral neuropathy in patients with HTLV-1 associated myelopathy/tropical spastic paraparesis (HAM/TSP)
Acta Neurol Belg, 111 (2011), pp. 41-44
14
S.M.D. Mendes,A.F. Baptista,K.N. Sá
Pain is highly prevalent in individuals with tropical spastic paraparesis
Health Care (Don Mills), 1 (2013), pp. 47-53
15
S.B. Santos,A.F. Porto,A.L. Muniz
Exacerbated inflammatory cellular immune response characteristics of HAM/TSP is observed in a large proportion of HTLV-I asymptomatic carriers
BMC Infect Dis, (2004), pp. 4
16
E.M. Carvalho,O. Bacellar,A.F. Porto,S. Braga,B. Galvão-Castro,F. Neva
Cytokine profile and immunomodulation in asymptomatic human T-lymphotropic virus type 1-infected blood donors
J Acquir Immune Defic Syndr, 27 (2001), pp. 1-6
17
C.M. De Castro-Costa,A. de Q.C. Araújo,C.C. Câmara
Pain in tropical spastic paraparesis/HTLV-I associated myelopathy patients
Arq Neuropsiquiatr, 67 (2009), pp. 866-870
18
A. Franzoi,A. Araújo
Disability and determinants of gait performance in tropical spastic paraparesis/HTLV-I associated myelopathy (HAM/TSP)
Spinal Cord, 45 (2007), pp. 64-68 http://dx.doi.org/10.1038/sj.sc.3101919
19
J.V.P. Martins,A.F. Baptista,A. de Q.C. Araújo
Quality of life in patients with HTLV-I associated myelopathy/tropical spastic paraparesis
Arq Neuropsiquiatr, 70 (2012), pp. 257-261
20
M.R.P. Gascón,C.G. Capitão,J. Casseb,M.C.F. Nogueira-Martins,J. Smid,A.C. Penalva de Oliveira
Prevalence of anxiety, depression and quality of life in HTLV-1 infected patients
Braz J Infect Dis, 15 (2011), pp. 578-582
21
E.C. Netto,C. Brites
Characteristics of chronic pain and its impact on quality of life of patients with HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP)
Clin J Pain, 27 (2011), pp. 131-135 http://dx.doi.org/10.1097/AJP.0b013e3181f195d3
22
C.M. De Castro-Costa,A.Q.C. Araújo,M.M. Barreto
Proposal for diagnostic criteria of tropical spastic paraparesis/HTLV-I-associated myelopathy (TSP/HAM)
AIDS Res Hum Retroviruses, 22 (2006), pp. 931-935 http://dx.doi.org/10.1089/aid.2006.22.931
23
T. Matsuzaki,M. Nakagawa,M. Nagai
HTLV-I-associated myelopathy (HAM)/tropical spastic paraparesis (TSP) with amyotrophic lateral sclerosis-like manifestations
J Neurovirol, 6 (2000), pp. 544-548
24
J.F. Kurtzke
Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS)
Neurology, 33 (1983), pp. 1444-1452
25
H. Merskey,N. Bogduk
Task force on taxonomy of the International Association for the Study of Pain: classification of chronic pain: descriptions of chronic pain syndromes and definitions of pain terms
IASP Press, (1994)
26
M.M.C. Castro,L. Quarantini,S. Batista-Neves,D.C. Kraychete,C. Daltro,Â. Miranda-Scippa
Validade da escala hospitalar de ansiedade e depressão em pacientes com dor crônica
Rev Bras Anestesiol, 56 (2006), pp. 470-477
27
L.M.S. Coutinho,M. Scazufca,P.R. Menezes
Métodos para estimar razão de prevalência em estudos de corte transversal
Rev Saude Publ, 42 (2008), pp. 992-998
28
I.R. Tavares,A.C. Franzoi,A.Q.-C. Araújo
Low-back pain in HTLV-I-associated myelopathy/tropical spastic paraparesis: nociceptive or neuropathic?
Spinal Cord, 48 (2010), pp. 134-137 http://dx.doi.org/10.1038/sc.2009.83
29
C.R.M. Bangham
HTLV-1 infections
J Clin Pathol, 53 (2000), pp. 581-586
30
C.R.M. Bangham
The immune control and cell-to-cell spread of human T-lymphotropic virus type 1
J Gen Virol, 84 (2003), pp. 3177-3189 http://dx.doi.org/10.1099/vir.0.19334-0
31
Y. Iwasaki
Pathology of chronic myelopathy associated with HTLV-I infection (HAM/TSP)
J Neurol ci, 96 (1990), pp. 103-123
32
V.L.S.de Britto,R. Correa,M.B. Vincent
Proprioceptive neuromuscular facilitation in HTLV-I-associated myelopathy/tropical spastic paraparesis
Rev Soc Bras Med Trop, 47 (2014), pp. 24-29 http://dx.doi.org/10.1590/0037-8682-0245-2013
33
L. Cartier,E. Ramirez
Presence of HTLV-I Tax protein in cerebrospinal fluid from HAM/TSP patients
Arch Virol, 150 (2005), pp. 743-753 http://dx.doi.org/10.1007/s00705-004-0443-3
34
J.G.R. Ribas,G.C.N. De Melo
Mielopatia associada ao vírus linfotrópico humano de células T do tipo 1 (HTLV-1)
Rev Soc Bras Med Trop, 35 (2002), pp. 377-384
35
C.T. Teng,E de C. Humes,F.N. Demetrio
Depressão e comorbidades clínicas
Rev Psiquiatr Clín, 32 (2005), pp. 149-159
36
AI de Loyola Filho,E. Uchoa,H.L. Guerra,J.O.A. Firmo,M.F. Lima-Costa
Prevalência e fatores associados à automedicação: resultados do projeto Bambuí
Rev Saude Publ, 36 (2002), pp. 55-62
37
P.S.D. Arrais,L.L. Brito,M.L. Barreto,H.L.L. Coelho
Prevalência e fatores determinantes do consumo de medicamentos no Município de Fortaleza, Ceará, Brasil
Cad Saude Publ, 21 (2005), pp. 1737-1746
38
F.E. Silverstein,G. Faich,J.L. Goldstein
Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis
JAMA, 284 (2000), pp. 1247-1255
39
L. Wannmacher,M. Bredemeier
Antiinflamatórios não-esteróides: Uso indiscriminado de inibidores seletivos de cicloxigenase-2
Fut Farmacêut, 1 (2004), pp. 1-6
40
G. Moseley
A pain neuromatrix approach to patients with chronic pain
Man Ther, 8 (2003), pp. 130-140
41
I.F. Neto,R.P. Mendonça,C.A. Nascimento,S.M.D. Mendes,K.N. Sá
Fortalecimento muscular em pacientes com HTLV-1 e sua influência no desempenho funcional: um estudo piloto
Rev Pesqui em Fisioter, 2 (2012), pp. 143-155
42
J. Borges,A.F. Baptista,N. Santana
Pilates exercises improve low back pain and quality of life in patients with HTLV-1 virus: a randomized crossover clinical trial
J Bodyw Mov Ther, 18 (2014), pp. 68-74 http://dx.doi.org/10.1016/j.jbmt.2013.05.010
43
J. Nijs,E. Kosek,J. Van Oosterwijck,M. Meeus
Dysfunctional endogenous analgesia during exercise in patients with chronic pain: to exercise or not to exercise?
Pain Phys, 15 (2012), pp. ES205-ES213
44
J.B. Souza
De. Poderia a atividade física induzir analgesia em pacientes com dor crônica?
Rev Bras Med do Esporte, 15 (2009), pp. 145-150
45
JB de Faria,E.M.F. Seidl
Religiosidade, enfrentamento e bem-estar subjetivo em pessoas vivendo com HIV/AIDS
Psicol Estud, 11 (2006), pp. 155-164
46
A. Moreira-Almeida,F. Lotufo Neto,H.G. Koenig
Religiousness and mental health: a review
Rev Bras Psiquiatr, 28 (2006), pp. 242-250
Copyright © 2016. Sociedade Brasileira de Infectologia
Braz J Infect Dis 2017;21:133-9 - Vol. 21 Num.2 DOI: 10.1016/j.bjid.2016.11.008